EBT-101 / Excision BioTherap - LARVOL DELTA

Toward an HIV cure: a review of the transformative potential of CRISPR/Cas9 in the quest for HIV cure (IAS-HIV 2025) - "Studies in non-human primates further supported its potential for clinical use.Human Clinical Trials: Early trials of EBT-101, a CRISPR-based therapy, showed that it was safe and well-tolerated... CRISPR/Cas9 presents a promising pathway for eradicating HIV-1 by targeting and excising proviral DNA. Yet, challenges like delivery efficiency, unintended genetic changes, and the variability of the virus need to be addressed. Continued research and innovation will be crucial to overcoming these barriers and achieving a functional HIV cure."

Review • Human Immunodeficiency Virus • Infectious Disease

CXCR4-Targeted CRISPR/Cas9 Lipid Nanoparticles for Excision of Latent Proviral DNA (CROI 2025) - "Recent clinical studies (EBT-101) using adeno-associated viral (AAV) vectors to deliver CRISPR for HIV eradication remained unsuccessful likely due to the limitations of AAV vectors, highlighting the need for alternative delivery systems like lipid nanoparticles (LNPs)...Furthermore, T-LNPs have shown superior excision efficiency compared to C-LNP in eliminating HIV-1 DNA from hu-mice infectious reservoirs. These data suggest that T-LNP has the potential to achieve a functional HIV-1 cure."

Lipid Nanoparticle • Human Immunodeficiency Virus • Infectious Disease • CD4 • CXCR4

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Excision BioTherapeutics | Active, not recruiting ➔ Completed | Trial completion date: May 2025 ➔ Nov 2024 | Trial primary completion date: May 2025 ➔ Nov 2024

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

CRISPR clinical trial with EBT-101 for HIV (using Excision therapeutics) (AIDS 2024) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Excision BioTherapeutics | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1 | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment closed • Phase classification • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4